The estimated Net Worth of Chris Nolet is at least $408 Thousand dollars as of 12 January 2023. Mr. Nolet owns over 36,497 units of Viela Bio stock worth over $360 and over the last 5 years he sold VIE stock worth over $0. In addition, he makes $407,957 as Independent Director at Viela Bio.
Sign up
Mr. Nolet VIE stock SEC Form 4 insiders trading
Chris has made over 1 trades of the Viela Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 36,497 units of VIE stock worth $912 on 12 January 2023.
The largest trade he's ever made was exercising 36,497 units of Viela Bio stock on 12 January 2023 worth over $912. On average, Chris trades about 2,807 units every 0 days since 2019. As of 12 January 2023 he still owns at least 14,403 units of Viela Bio stock.
You can see the complete history of Mr. Nolet stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Chris Nolet biography
Chris Nolet CPA serves as Independent Director of the Company. From 2002 to June 2019, Mr. Nolet was the West Region Life Sciences Industry Leader & Partner at Ernst & Young (EY) and has more than 38 years of experience in the profession. In addition to serving a wide array of clients, his responsibilities included leading West Region EY Life Sciences Industry Group, and serving as a member of the Global EY Life Sciences Executive Leadership Group, which established policies and operating strategies for EY Life Sciences practice worldwide. He currently serves on both the Executive Committee and Finance Committee (Co-Chair) of the California Life Sciences Industry Association, the board of directors of Revance Therapeutics, Inc., a biotechnology company, and is a former member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization. Prior to joining EY, Mr. Nolet was a partner at PricewaterhouseCoopers where he led the Life Sciences practice in the western U.S. Mr. Nolet has a B.S. in Accounting from San Diego State University and is a Certified Public Accountant in California.
What is the salary of Chris Nolet?
As the Independent Director of Viela Bio, the total compensation of Chris Nolet at Viela Bio is $407,957. There are 4 executives at Viela Bio getting paid more, with Zhengbin Yao having the highest compensation of $2,747,550.
How old is Chris Nolet?
Chris Nolet is 63, he's been the Independent Director of Viela Bio since 2019. There are no older and 11 younger executives at Viela Bio.
What's Chris Nolet's mailing address?
Chris's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, 20TH FLOOR, NASHVILLE, TN, 37203.
Insiders trading at Viela Bio
Over the last 5 years, insiders at Viela Bio have traded over $58,712,400 worth of Viela Bio stock and bought 1,261,091 units worth $24,062,867 . The most active insiders traders include Andreas Wicki, Xiaomeng Tong, and Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of $6,348. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth $5,680.
What does Viela Bio do?
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
What does Viela Bio's logo look like?
Complete history of Mr. Nolet stock trades at Revance Therapeutics Inc, PolarityTE Inc, and Viela Bio
Viela Bio executives and stock owners
Viela Bio executives and other stock owners filed with the SEC include:
-
Zhengbin Yao,
Chairman of the Board, President, Chief Executive Officer -
Jorn Drappa,
Chief Medical Officer, Head of Research and Development -
Mitchell Chan,
Chief Financial Officer -
Aaron Ren,
Vice President - Head of Business Development and Operations -
Chris Nolet,
Independent Director -
Edward Hu,
Independent Director -
Yanling Cao,
Director -
Chad Rubin,
IR Contact Officer -
Andreas Wicki,
Independent Director -
Tyrell Rivers,
Independent Director -
Rachelle Jacques,
Independent Director -
Sean Tong,
Director -
Jim Kastenmayer,
General Counsel, Secretary -
William Ragatz,
Vice President - Head of Commercial -
Xiaomeng Tong,
Director -
Plc Astra Zeneca Uk Ltd Ast...,
-
Meadow Ltd Boundless,
10% owner -
James Paul Kastenmayer,
General Counsel -
Meadow Ltd Boyu Capital Fun...,